



# JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB

Official Journal of [The Association for Mass Spectrometry & Advances in the Clinical Lab \(MSACL\)](#)

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

---

- **Description** **p.1**
- **Editorial Board** **p.1**
- **Guide for Authors** **p.5**

ISSN: 2667-145X

### DESCRIPTION

---

*Journal of Mass Spectrometry and Advances in the Clinical Lab* publishes peer-reviewed articles addressing the application of mass spectrometric technologies in Laboratory Medicine and Clinical Pathology with a focus on diagnostic applications. It is the first journal dedicated specifically to the application of mass spectrometry and related techniques in the context of diagnostic procedures in medicine. The journal has an interdisciplinary approach aiming to link clinical, biochemical and technological issues and results.

Beyond the application of mass spectrometric technologies in the routine clinical diagnostic setting, by publishing critically validated analytical protocols, *Journal of Mass Spectrometry and Advances in the Clinical Lab* also addresses the translation of experimental techniques and analytical research into patients' care and the use of mass spectrometry in clinical research, studies, and routine patient care. The scope of the journal is not restricted to any particular mass spectrometric technologies, but covers the entire methodological range of mass spectrometry and hyphenated technologies.

In addition to manuscripts directly targeting patient care, the journal will consider Basic and/or Translational research with Clinical Implications on the pathway to patient care.

Subject areas covered by the journal include, but are not restricted to: Endocrinology Protein quantification Therapeutic drug monitoring Toxicology Neonatal screening Clinical lipidomics Clinical glycomics Clinical metabolomics and metabolic analyses Protein variant detection Microbiology Imaging On-site technologies New technologies including automation Data Science Cross technology investigations Validation, standardization and quality management Reference methods, materials and measurement services Regulatory aspects in diagnostic applications Mass spectrometry based clinical studies Error sources, risk assessment and patient safety

Types of papers: Reviews, mini-reviews, full papers, short papers (letters, case studies, protocols, application notes), guidelines and best practice documents, tutorials, invited editorials.

### EDITORIAL BOARD

---

#### **Co-Editors-in-Chief**

**Alan L. Rockwood**, University of Utah School of Medicine  
Laboratory Medicine, MS Fundamentals, MS Instrumentation Development, Clinical Chemistry, Small molecules, Proteins and Peptides

**Michael Vogeser**, Ludwig Maximilians University Munich, Munich, Germany  
Laboratory Medicine, Translational Diagnostics, Therapeutic Drug Monitoring, Endocrinology Quality and Risk Management in Mass Spectrometry and in Clinical Testing

## **Managing Editor**

**Chris Herold**, MSACL, Del Mar, California, United States

## **Editors**

**Jean Armengaud**, French Alternative Energies and Atomic Energy Commission Marcoule, Bagnols-sur-Cèze, France

Microbiology, Proteomics, Sample Prep, Virulence factors, Sample Prep, Bioinformatics, MALDI-TOF, Diagnostics, Biomarkers, CBRN, MS/MS for Pathogen Detection, Microbiomes

**Erin Shammel Baker**, North Carolina State University, Raleigh, North Carolina, United States

Instrumentation, Advanced Technology, Metabolomics

**Anne Bendt**, National University of Singapore, Singapore

Lipidomics

**Clifton Fagerquist**, USDA-ARS Produce Safety and Microbiology Research, Albany, California, United States

Microbiology, Proteomics

**Tim Garrett**, University of Florida, Gainesville, Florida, United States

Metabolomics

**Ronda Greaves**, RMIT University, Melbourne, Victoria, Australia

Small Molecules, Endocrinology, Regs & Standards, Pediatrics / Vitamins

**Grace van der Gugten**, The University of British Columbia, Vancouver, British Columbia, Canada

Small Molecules, Clinical Implementation, Education, Training, Certification

**Daniel Holmes**, The University of British Columbia, Vancouver, British Columbia, Canada

Lipidology, Endocrinology, Small Molecules, Sample Prep, Automation, Utilization of mathematics and computer diagnostics in laboratory medicine

**Julijana Ivanisevic**, University of Lausanne, Lausanne, Switzerland

Metabolomics

**Randy Julian**, Indigo BioAutomation, Carmel, Indiana, United States

Clinical Application of Informatics

**Gabi Kastenmüller**, Helmholtz Center Munich German Research Center for Environmental Health, Neuherberg, Germany

Bioinformatic tools and databases for metabolomics data analysis and data interpretation, Metabolome-wide and genome-wide association studies

**Mark Kushnir**, ARUP Laboratories, Salt Lake City, Utah, United States

Small Molecules, Proteomics

**Chia-Ni Lin**, Chang Gung Memorial Hospital Department of Laboratory Medicine, Taoyuan, Taiwan

Small Molecules

**Kara Lynch**, University of California San Francisco, San Francisco, California, United States

TDM / Toxicology

**Gwen McMillin**, ARUP Laboratories, Salt Lake City, Utah, United States

Toxicology, Pain Management, Clinical Pharmacogenomics, Neonatal Drug Exposure

**Jody van den Ouweland**, Canisius Wilhelmina Hospital, Nijmegen, Netherlands

Small Molecules, Endocrinology, TDM, Vitamins, Steroids

**Katharina Rentsch**, University Hospital Basel, Basel, Switzerland

TDM, Toxicology, Regulations & Standards

**Elizabeth Want**, Imperial College London Faculty of Medicine, London, United Kingdom

Metabolomics, Sample Prep

**Manfred Wuhrer**, Leiden University Medical Center Center for Proteomics and Metabolomics, Leiden, Netherlands

Antibodies, Glycoprotein Pathways, Glycoprotein Secretion, Glycoprotein Structure, Glycoproteins, Glycoproteomics, Immunoaffinity, Plasma or serum analysis, Post-translational modifications, Tandem Mass Spectrometry, mass spectrometry (MS), mass spectrometry (MS), mass spectrometry (MS), glycoprotein structure, glycoprotein structure, glycoprotein structure, glycoconjugate, glycoconjugate, glycoconjugate, glycoprotein, glycoprotein, glycoprotein.

**Yan Victoria Zhang**, University of Rochester Medical Center, Rochester, New York, United States

Small Molecules, Proteomics

## **Advisory Board**

**Jonas Bergquist**, Uppsala University, Uppsala, Sweden

Proteomics, Endocrinology, Sample Prep, Tissue Imaging

**Michael Gelb**, University of Washington, Seattle, Washington, United States

Small Molecules, Newborn Screening

**Ron Heeren**, Maastricht University, Maastricht, Netherlands

Tissue Imaging, Sample Prep

**David Herold**, University of California San Diego, La Jolla, California, United States

Small Molecules, Clinical Application

**Donald Hunt**, University of Virginia, Charlottesville, Virginia, United States

Proteomics

**Alexander Makarov**, Thermo Fisher Scientific (Bremen) GmbH, Bremen, Germany

Proteomics, Small Molecules, Instrumentation

**Matthias Mann**, Max Planck Institut (MPI) für Biochemie, Department of Proteomics and Signal Transduction, Martinsried, Germany

Mass Spectrometry, Protein Identification, Protein-Protein Interactions, Quantification, SILAC, Tandem Mass Spectrometry.

**David Millington**, Duke University Department of Pediatrics, Durham, North Carolina, United States

Small Molecules, Metabolomics, Newborn Screening, Population and Newborn Screening

**Kenneth Setchell**, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Small Molecules, Pediatrics

**Jentaie Shiea**, National Sun Yat-sen University, Kaohsiung, Taiwan

Toxicology, Small Molecules, Ionization, Ambient Ionization Mass Spectrometry

**Ravinder Singh**, Mayo Clinic Rochester, Rochester, Minnesota, United States

Endocrinology, Metabolomics, Proteomics

**Richard Smith**, Pacific Northwest National Laboratory, Richland, Washington, United States

Proteomics, Metabolomics, Separations

**Junghan Song**, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

TDM, Endocrinology, Newborn Screening

**Zoltan Takats**, Imperial College London, London, United Kingdom

Tissue Imaging, Metabolomics, Proteomics, In vivo

**Linda Thienpont**, Ghent University, Ghent, Belgium

Regulations & Standards

**Rick Yost**, University of Florida, Gainesville, Florida, United States

Tissue Imaging, Metabolomics, MS Instrumentation

#### **Editorial Board**

**Jan-Willem Alffenaar**, University Medical Centre, Utrecht, Netherlands

TDM, Toxicology, DBS Analysis, Clinical Pharmacology

**Leigh Anderson**, SISCAPA Assay Technologies Inc, Washington, District of Columbia, United States

Proteomics, Sample Prep

**David Barnidge**, Mayo Clinic Rochester, Rochester, Minnesota, United States

Proteomics, TDM, Immunology, Hematology

**Bertrand Rochat**, University of Lausanne, Lausanne, Switzerland

Small Molecules, Metabolomics, Drug Metabolism, Mass Spectrometry, LC-MS

**Julianne Botelho**, Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Endocrinology, Regs & Standards, Small Molecules

**Irene Burckhardt**, Heidelberg University, Heidelberg, Germany

Microbiology, Infectious Diseases

**Carey-Ann Burnham**, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States

Microbiology

**Uta Ceglarek**, Leipzig University, Leipzig, Germany

Small Molecules, Metabolomics, Proteomics

**Nigel Clarke**, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, United States

Proteomics, Endocrinology, TDM, Small Molecules

**William Clarke**, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

TDM, Toxicology

**Laurent Decosterd**, University of Lausanne, Lausanne, Switzerland

TDM, Small Molecules

**Bruno Domon**, Luxembourg Institute of Health, Strassen, Luxembourg

Proteomics, Sample Prep

**Mark Duncan**, University of Colorado Denver, United States

Endocrinology, Small Molecules, Diagnostic Assay Development, Quantification

**Jennifer van Eyk**, Cedars-Sinai Heart Institute, Los Angeles, California, United States

Proteomics, Sample Prep, Assay Development

**Robert Fitzgerald**, Howard Hughes Medical Institute - University of California San Diego School of Medicine, San Diego, California, United States

Toxicology, Endocrinology, Small Molecules

**Roland Geyer**, Inselspital University Hospital Bern, Switzerland

Metabolomics, Small Molecules, Lipidomics, Lipidomics, Validation

**Stefan Grebe**, Mayo Clinic Rochester, Rochester, Minnesota, United States

Endocrinology, Proteomics

**William Griffiths**, Swansea University, Swansea, United Kingdom  
Metabolomics, Endocrinology, Sample Prep

**Kamisha Johnson-Davis**, ARUP Laboratories, Salt Lake City, Utah, United States  
Toxicology, TDM, Regs & Standards

**Brian Keevil**, The University of Manchester, Manchester, United Kingdom  
Small Molecules, Endocrinology

**Michael MacCoss**, University of Washington Medical Center, Seattle, Washington, United States  
Proteomics, Bioinformatics, Sample Prep

**Stephen Master**, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA  
Bioinformatics, Proteomics, Statistics

**Oleg Mayboroda**, Leiden University Medical Center Center for Proteomics and Metabolomics, Leiden, Netherlands  
Metabolomics, Bioinformatics, Infectious Diseases, Parasitology, Nephrology

**Dobrin Nedelkov**, Isoformix, Phoenix, Arizona, United States  
Proteomics, Sample Prep

**Mirko Peitzsch**, Dresden University Hospital, Dresden, Germany  
Endocrinology, Small Molecules

**Brian Rappold**, Laboratory Corporation of America Research Triangle Park, Research Triangle Park, North Carolina, United States

**Maria Shipkova**, University of Stuttgart, Stuttgart, Germany  
TDM, Toxicology

**Hubert Vesper**, Centers for Disease Control and Prevention, Atlanta, Georgia, United States  
Regs & Standards, Endocrinology, Sample Preparation, Cardiovascular Diseases

**Yuqin Wang**, Swansea University, Swansea, United Kingdom  
Metabolomics, Proteomics

**Steven Wong**, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States  
TDM, Metabolomics, Toxicology, Automation, Next Generation Mass Spectrometry

**Yeo-Min Yun**, Konkuk University School of Medicine, Gwangjin-gu, Korea, Republic of  
Endocrinology, TDM

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

*Journal of Mass Spectrometry and Advances in the Clinical Lab* publishes quality peer-reviewed articles addressing the application of mass spectrometric technologies in Laboratory Medicine and Clinical Pathology with the focus on diagnostic applications. It is the first journal dedicated specifically to the application of mass spectrometry and related techniques in the context of diagnostic procedures in medicine. The journal has an interdisciplinary approach aiming to link clinical, biochemical and technological issues and results. Beyond the application of mass spectrometric technologies in the routine clinical diagnostic setting, by publishing critically validated analytical protocols, *Clinical Mass Spectrometry* also addresses the translation of experimental techniques and analytical research into patients' care and the use of mass spectrometry in clinical research, studies, and routine patient care. The scope of the journal is not restricted to any particular mass spectrometric technologies but covers the entire methodological range of mass spectrometry and hyphenated technologies. In addition to manuscripts directly targeting patient care, the journal will consider Basic and/or Translational research with Clinical Implications on the pathway to patient care.

Subject areas covered by the journal include, but are not restricted to: Endocrinology; Protein quantification; Therapeutic drug monitoring; Toxicology; Neonatal screening; Clinical Lipidomics; Clinical Glycomics; Clinical metabolomics and metabolic analyses; Protein variant detection; Microbiology; Imaging; On-site technologies; New technologies including automation; Data analysis and informatics including result reporting; Cross technology investigations; Validation, standardization and quality management; Reference methods, materials and measurement services; Regulatory aspects in diagnostic applications; Mass spectrometry based clinical studies; Error sources, risk assessment and patient safety.

### *Types of paper*

Reviews, Mini-reviews, Full papers, Short papers (letters, case studies, protocols, application notes), Graphical Reviews, Guidelines and best practice documents, Tutorials, Invited editorials.

*Clinical Mass Spectrometry* introduces Graphical Reviews: These reviews will summarize schematically key concepts, established and novel ideas in clinical mass spectrometry which will be accessible to a broad audience and freely downloaded as PowerPoint slides for use in teaching or conference presentations. Examples: <https://doi.org/10.1016/j.biopen.2018.05.001> and <https://doi.org/10.1016/j.redox.2012.10.001>

### *Contact details*

Customer support is available 24/7: Please use our Support Center at: <https://service.elsevier.com>. Here you will be able to learn more about the online submission system via interactive tutorials, explore a range of problem solutions via our knowledgebase, and find answers to frequently asked questions. You will also find our 24/7 support contact details should you need any assistance from one of our customer service representatives. For publishing queries please contact Anthony Newman, Laboratory Medicine journals Publisher at Elsevier: [a.newman@elsevier.com](mailto:a.newman@elsevier.com)

Articles for *Clinical Mass Spectrometry* should be submitted via the journal online submission system.

### *Page charges*

This journal has no page charges.

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Abstract must be in a [Structured Format](#)
- Include under the abstract an alphabetical listing of all abbreviations used in the document
- Include keywords under the abbreviations
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print  
*Graphical Abstracts / Highlights files* (where applicable)
- Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Immediately prior to your References section, a competing interests (conflict of interest) statement must be provided for each author. Use the [form that is downloadable from the ICJME website](#) to determine the authors' competing interest statements. If the authors have no competing interests to declare, please state for each author "[author name] has no competing interests to declare" or as recommended by the ICJME form
- Immediately following the Competing Interests Statement, please include any IRB information, if included as part of your study
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### **Ethics**

The authors wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

### **POLICY AND ETHICS**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. This must be stated at an appropriate point in the article.

Please note: Clinical Mass Spectrometry does not normally accept submission of papers based on animal studies.

STARD initiative [Clinical Mass Spectrometry supports the STARD initiative on reporting of diagnostic accuracy](#)

### **CONFLICT OF INTEREST**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work or be perceived by others to potentially influence their work. Examples of potential conflicting interests include employment, consultancies, stock

ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Each co-author must complete an ICMJE Conflict of Interest Form and submit it to the corresponding author. Although the ICMJE form requires "potential" and "relevant" conflicts, to promote transparency we request authors to report all financial relationships including individual stocks where the amount of the stock as of the date of COI signing is greater than \$10,000/10,000. Mutual funds need not be listed. Such disclosure will not affect the review of the manuscript. All submissions must have the ICMJE Conflict of Interest Form completed and uploaded for each author, preferably as part of the initial submission process, but no later than first revision. The form posted on the ICMJE website and enclosed in our guide as a includes instructions to help authors provide the correct information. For non-native English speakers, there is a glossary of terms that are used in the form. Every published manuscript also needs to have a matching statement added by the authors at the end of the paper, before the references. If none, then please add: "Conflict of Interest: None of the authors has any conflicts of interest to disclose." If there are conflicts to declare please add: "Conflict of Interest: Authors with financial interests or relationships to disclose are listed with their details below." Corresponding authors are asked to confirm or update conflict of interest statements as part of the final steps before submitting the revised manuscript.

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

### **Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Open access**

Please visit our [Open Access page](#) for more information.

### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's Author Services.

### **Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the [Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals](#). Unless



you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

#### *INSTITUTIONAL REVIEW BOARD*

If the study involved human subjects, human-derived materials, or human medical records, please include one of the two following statements in the Methods section: Institutional Review Board (IRB)/Ethics Committee approval was obtained OR Institutional Review Board (IRB)/Ethics Committee ruled that approval was not required for this study. For Report submissions only: If institution's IRB does not require approval for case reports, provide an exemption letter or public URL that reiterates the policy that approval is not needed

#### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

A minimum of six suitable potential reviewers must be supplied (please provide their name, email addresses, and institutional affiliation). When compiling this list of potential reviewers please consider the following important criteria: they must be knowledgeable about the manuscript subject area; must not be from your own institution; at least two of the suggested reviewers should be from another country than the authors'; and they should not have recent (less than four years) joint publications with any of the authors. However, the final choice of reviewers is at the editors' discretion.

### **PREPARATION**

#### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

#### *References*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

#### *Formatting requirements*

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

#### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

#### **Peer review**

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors

are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. [More information on types of peer review.](#)

## **REVISED SUBMISSIONS**

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## **Article structure**

### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

### *Theory/calculation*

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Glossary*

Please supply, as a separate list, the definitions of field-specific terms used in your article.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-

case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### Highlights

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

### Structured abstract

A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations.

An abstract is often presented separately from the article, so must be concise (limit of 250 words) and able to stand alone. Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Please use the example [from the National Library of Medicine](#) as a template for your structured abstract. Review articles do not require a structured abstract, unless the author thinks this appropriate.

### Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

### Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### *Nomenclature and units*

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult [IUB: Biochemical Nomenclature and Related Documents](#) for further information.

### *Math formulae*

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

## **Artwork**

### *Image manipulation*

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

### *Electronic artwork*

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites). [Further information on the preparation of electronic artwork](#).

### *Illustration services*

[Elsevier's Author Services](#) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

### **References**

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software](#).

### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### *Reference style*

*Text:* Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

*List:* Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

### *Examples:*

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

[2] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, 2018. The art of writing a scientific article. *Heliyon.* 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book:

[3] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[4] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

Reference to a website:

[5] Cancer Research UK, *Cancer statistics reports for the UK*. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>, 2003 (accessed 13 March 2003).

Reference to a dataset:

[dataset] [6] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt disease and surrounding forest compositions, *Mendeley Data*, v1, 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#). *Clinical Mass Spectrometry* should be abbreviated to Clin. Mass Spectrom.

### **Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

#### *Supplementary material captions*

Each supplementary material file should have a short caption which will be placed at the bottom of the article, where it can assist the reader and also be used by search engines.

### **Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

#### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data in Brief*

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for *Data in Brief* as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the open access data journal, *Data in Brief*. Please note an open access fee of 600 USD is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

## **AFTER ACCEPTANCE**

### **Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Author Services](#). Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).